ESR1 and breast carcinoma: However, ER + advanced breast cancer patients with intrinsic resistance to endocrine therapy and treated with combined CDK4/6i and endocrine therapy whose tumors expressed low AURKA exhibited significantly shorter PFS (Supplementary Fig. 9d).